Spoken Alpha
Nexentis Technologies Inc.
Nexentis Technologies Inc. operates through its wholly-owned subsidiary MitoCareX Bio, a drug discovery company developing small-molecule cancer therapeutics targeting mitochondrial carrier proteins (SLC25A family) to treat non-small cell lung cancer and pancreatic cancer.
Nexentis Technologies Inc is a Basic Materials company operating in Agricultural Inputs with a $2.2M market cap.
Most recent reported earnings: Q2 FY2026 (Aug 12, 2026).
Behavioral analysis
Disclosures
Transcripts
We index calls for roughly 3,000 US-listed companies. If you'd like us to add NXTS, reply to your welcome email and we'll prioritize it.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for NXTS.
$ curl https://api.spokenalpha.com/v1/companies/NXTSFAQ
Spoken Alpha indexes NXTS's earnings call transcripts at https://spokenalpha.com/companies/NXTS. Each call links to attributed speakers and parsed analyst Q&A.
Nexentis Technologies Inc. (NXTS) operates in the Basic Materials sector (Agricultural Inputs industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-12 | $-25.96 | — | — | $0 | — | — | EODHD |
| Q1 FY2026 | 2026-03-30 | $-10.74 | — | — | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-09-29 | $3.18 | — | — | $2.0K | — | — | EODHD |
| Q2 FY2025 | 2025-06-29 | $-44.39 | — | — | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-05-14 | $-0.39 | — | — | $66.0K | — | — | EODHD |
| Q4 FY2024 | 2024-12-30 | $-27.89 | — | — | $140.5K | — | — | EODHD |
| Q3 FY2024 | 2024-09-29 | $-95.27 | — | — | $9.0K | — | — | EODHD |
| Q2 FY2024 | 2024-06-29 | $-56.59 | — | — | $17.0K | — | — | EODHD |
| Q1 FY2024 | 2024-03-30 | $-63.68 | — | — | $43.8K | — | — | EODHD |
| Q4 FY2023 | 2023-12-30 | $-181.12 | — | — | $105.8K | — | — | EODHD |
| Q3 FY2023 | 2023-09-29 | $-3047.92 | — | — | — | — | — | EODHD |
| Q2 FY2023 | 2023-06-29 | $-174.18 | — | — | $36.6K | — | — | EODHD |
| Q1 FY2023 | 2023-03-30 | $-629.56 | — | — | $121.0K | — | — | EODHD |
| Q4 FY2022 | 2022-12-30 | $-517.97 | — | — | $224.1K | — | — | EODHD |
| Q3 FY2022 | 2022-09-29 | $-815.15 | — | — | $51.2K | — | — | EODHD |
| Q2 FY2022 | 2022-06-29 | $-752.89 | — | — | $31.1K | — | — | EODHD |
| Q1 FY2022 | 2022-03-30 | $-808.91 | — | — | $87.6K | — | — | EODHD |
| Q4 FY2021 | 2021-12-30 | $-953.06 | — | — | $189.3K | — | — | EODHD |
| Q3 FY2021 | 2021-09-29 | $-792.17 | — | — | $71.4K | — | — | EODHD |
| Q2 FY2021 | 2021-06-29 | $-1176.83 | — | — | $54.4K | — | — | EODHD |
Source: EODHD. NXTS reported actuals as published; sparse fields render as —.